743 studies found for:    Open Studies | "Lymphoma, Non-Hodgkin"
Show Display Options
Rank Status Study
21 Recruiting Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Hematopoetic Myelodysplasia;   Leukemia, Myelogenous, Chronic;   Lymphoma, Non-Hodgkin
Intervention: Drug: Sitagliptin
22 Unknown  Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplasia;   Lymphoma, Non-Hodgkin;   Hodgkin's Lymphoma;   Multiple Myeloma
Intervention: Drug: Clioquinol
23 Recruiting Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Other: Database
24 Recruiting Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
25 Recruiting Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Intervention: Drug: Abraxane
26 Recruiting IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Conditions: Lymphoma, Non-Hodgkin;   Chronic Lymphocytic Leukemia
Intervention: Drug: IMGN529
27 Unknown  Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Intervention: Procedure: Cytogenetic Analysis of Bone Marrow Specimen
28 Recruiting Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)
Conditions: Lymphoma, Non-Hodgkin;   Malaria;   Herpesvirus 4, Human
Intervention:
29 Not yet recruiting BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Rituximab;   Drug: BI 695500
30 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
31 Recruiting Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Biological: Ofatumumab;   Drug: Bendamustine
32 Unknown  Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation
Conditions: Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: proton pump inhibitor;   Drug: clarithromycin;   Drug: amoxicillin;   Drug: metronidazole;   Procedure: radiation therapy
33 Recruiting Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Drug: SD-101;   Radiation: Local Radiation
34 Recruiting Molecular and Whole-body MR Imaging in Lymphomas
Conditions: Lymphoma;   Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Other: 68Ga-DOTANOC PET/CT; Diffusion weighted MRI
35 Recruiting FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Conditions: Lymphoma;   Lymphoma, Non-Hodgkin;   Large B Cell Diffuse Lymphoma
Interventions: Procedure: FLT-PET/CT;   Procedure: FDG-PET/CT;   Drug: FLT
36 Not yet recruiting A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: Obinutuzumab;   Drug: CC-122
37 Recruiting Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Leukemia Acute Myeloid;   Lymphoma, Non-Hodgkin;   Myelodysplastic Syndrome;   Immunologic Deficiency Syndromes
Intervention: Biological: BPX-501 T cells and AP1903
38 Recruiting A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: PF-05082566;   Drug: rituximab
39 Recruiting Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Other: Ribomustin;   Other: rituximab
40 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years